#1 Clinical Trials Search in Europe

Pertechnetate (99Mtc) Sodium

This article discusses a clinical trial investigating the use of Pertechnetate (99mTc) Sodium, along with indocyanine green (ICG), for sentinel node detection in patients with early-stage epithelial ovarian cancer. The study aims to evaluate the efficiency and precision of these tracers in identifying sentinel lymph nodes, which could potentially improve the staging and treatment of ovarian cancer.

Table of Contents

What is PERTECHNETATE (99MTC) SODIUM?

PERTECHNETATE (99MTC) SODIUM, also known as Sodium pertechnetate (99mTc), is a radioactive substance used in medical imaging[1]. It’s classified as a radiopharmaceutical, which means it’s a drug containing a radioactive isotope used for diagnostic or therapeutic purposes in nuclear medicine.

Medical Use in Early-Stage Ovarian Cancer

This substance is being studied for its potential use in detecting sentinel lymph nodes in patients with early-stage epithelial ovarian cancer[1]. Epithelial ovarian cancer is a type of cancer that begins in the cells lining the ovaries. Early detection of cancer spread to lymph nodes is crucial for proper staging and treatment planning.

How Does It Work?

PERTECHNETATE (99MTC) SODIUM works as a tracer. When injected near the tumor site, it travels through the lymphatic system and collects in the sentinel lymph nodes – the first lymph nodes where cancer cells are likely to spread[1]. Special cameras can then detect the radioactive signal, helping surgeons locate these important nodes.

How is It Administered?

The drug is administered as an injectable solution[1]. It’s typically injected near the tumor site before surgery. The maximum daily dose is 400,000,000 Bq (becquerels), which is a unit used to measure radioactivity[1].

Current Clinical Trial

A clinical trial is currently underway to evaluate the effectiveness of PERTECHNETATE (99MTC) SODIUM in sentinel node detection for early-stage ovarian cancer[1]. The study aims to:

  • Assess how well the tracer can detect sentinel lymph nodes
  • Evaluate the precision of sentinel lymph node detection
  • Study the lymphatic drainage patterns in ovarian cancer
  • Compare the performance of different detection techniques
  • Examine the anatomical distribution of sentinel lymph nodes

Who is Eligible for the Trial?

The trial is open to patients who meet specific criteria[1]:

  • Women with suspected or confirmed early-stage epithelial ovarian cancer
  • No evidence of cancer spread to lymph nodes or distant sites on imaging
  • Able to undergo surgery
  • 18 years of age or older
  • Not pregnant or breastfeeding

Potential Benefits

If successful, this technique could offer several benefits[1]:

  • More accurate staging of ovarian cancer
  • Improved detection of small metastases in lymph nodes
  • Potentially less extensive surgery if unnecessary lymph node removal can be avoided
  • Better understanding of how ovarian cancer spreads through the lymphatic system

Precautions and Exclusions

Certain conditions may prevent participation in the trial[1]:

  • Advanced stage ovarian cancer (FIGO stage III or IV)
  • History of vascular surgery or radiation therapy in the pelvic or para-aortic area
  • Hypersensitivity to the active ingredient or iodine allergy
  • Clinical hyperthyroidism or certain thyroid conditions

It’s important to note that while this treatment shows promise, it’s still under investigation. Patients should discuss all potential risks and benefits with their healthcare provider before considering participation in any clinical trial.

Aspect Details
Study Title Sentinel node detection with 99Tc albumin nanocolloid and indocianine green (ICG) in patients with epithelial ovarian cancer in early stages. Pilot study.
Main Objective To evaluate the diagnostic efficiency of both tracers in sentinel lymph node detection
Target Population Patients with early-stage epithelial ovarian cancer
Primary Endpoint Global detection rate of sentinel lymph node in patients having received both tracers
Key Secondary Endpoints Diagnostic precision, detection rates by tracer and technique, anatomical location of sentinel nodes, pathology ultrastaging evaluation
Study Design Single-arm study where all patients receive both tracers
Investigational Product Pertechnetate (99mTc) Sodium (Tekcis 2-50 GBq radionuclide generator)
Maximum Daily Dose 400,000,000 Bq
Route of Administration Injectable solution

FAQ

  • What is the main purpose of this clinical trial? The main purpose of this clinical trial is to evaluate the diagnostic efficiency of two tracers, Pertechnetate (99mTc) Sodium and indocyanine green (ICG), in detecting sentinel lymph nodes in patients with early-stage epithelial ovarian cancer.
  • Who can participate in this clinical trial? Patients with a high suspicion of malignant adnexal mass or those already diagnosed with early-stage epithelial ovarian cancer are eligible. Participants must be at least 18 years old, not pregnant or breastfeeding, and have no signs of advanced disease or previous pelvic/para-aortic radiotherapy.
  • What procedures will be performed during the trial? Participants will receive both tracers (Pertechnetate (99mTc) Sodium and ICG) for sentinel lymph node detection. The study will use intraoperative gamma probe detection and near-infrared (NIR) camera imaging to map the ovarian lymphatic system and locate sentinel nodes.
  • What are the potential benefits of this study? This study may lead to improved detection of sentinel lymph nodes in ovarian cancer, potentially enhancing staging accuracy and treatment planning. It may also help in understanding the lymphatic drainage patterns in ovarian cancer and improve the detection of micrometastases through ultrastaging techniques.
  • Are there any risks associated with participating in this trial? While the trial aims to evaluate complications associated with each technique, the use of radioactive tracers and surgical procedures may carry some risks. Patients with hypersensitivity to the active ingredients or iodine allergy are excluded from the study to minimize potential adverse reactions.

Ongoing Clinical Trials on Pertechnetate (99Mtc) Sodium

  • Study on Sentinel Lymph Node Technique in Early-Stage Ovarian Cancer Using Pertechnetate (99mTc) Sodium, Human Serum Albumin, and Indocyanine Green

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study on Sentinel Node Detection Using Technetium-99m and Indocyanine Green in Patients with Early-Stage Ovarian Cancer

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Spain

Glossary

  • Sentinel lymph node: The first lymph node(s) to which cancer cells are most likely to spread from a primary tumor.
  • Pertechnetate (99mTc) Sodium: A radioactive tracer used in medical imaging to help detect and visualize specific tissues or organs in the body.
  • Indocyanine green (ICG): A fluorescent dye used in medical diagnostics to help visualize blood vessels, tissues, and lymphatic systems.
  • Epithelial ovarian cancer: A type of cancer that begins in the cells lining the ovaries or fallopian tubes.
  • FIGO stage: A system used to describe the extent of ovarian cancer, developed by the International Federation of Gynecology and Obstetrics.
  • Adnexal mass: A growth that occurs in or near the uterus, ovaries, or fallopian tubes.
  • Micrometastases: Very small collections of cancer cells that have spread from the primary tumor to other parts of the body.
  • Ultrastaging: An advanced pathological examination technique that involves more detailed analysis of tissue samples to detect small cancer deposits.
  • NIR camera: Near-infrared camera, used to visualize fluorescent dyes like ICG during surgical procedures.
  • Gamma probe: A handheld device used to detect radioactive tracers in the body during surgery.

References

  1. http://clinicaltrials.eu/trial/study-on-sentinel-node-detection-using-technetium-99m-and-indocyanine-green-in-patients-with-early-stage-ovarian-cancer/